Headlands Technologies LLC Makes New Investment in Edwards Lifesciences Corporation $EW

Headlands Technologies LLC bought a new position in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 10,451 shares of the medical research company’s stock, valued at approximately $945,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Hanson & Doremus Investment Management bought a new position in shares of Edwards Lifesciences in the first quarter worth about $25,000. JPL Wealth Management LLC purchased a new position in Edwards Lifesciences in the 3rd quarter worth about $25,000. MV Capital Management Inc. purchased a new position in Edwards Lifesciences in the 4th quarter worth about $26,000. RMG Wealth Management LLC bought a new stake in Edwards Lifesciences during the 1st quarter valued at about $26,000. Finally, Pin Oak Investment Advisors Inc. bought a new stake in Edwards Lifesciences during the 2nd quarter valued at about $26,000. 79.46% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Evercore reiterated an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a report on Monday, July 6th. Truist Financial boosted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Finally, Citigroup increased their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Stock Up 0.0%

NYSE:EW opened at $90.78 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The company has a 50-day moving average of $89.71 and a 200 day moving average of $85.26. The firm has a market cap of $52.27 billion, a PE ratio of 52.17, a price-to-earnings-growth ratio of 2.38 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter last year, the firm posted $0.67 EPS. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Activity

In related news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the transaction, the senior vice president directly owned 14,868 shares in the company, valued at approximately $1,353,880.08. The trade was a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 5,045 shares of company stock worth $457,749. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.